Skip to main content


Fig. 1 | BMC Medicine

Fig. 1

From: Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis

Fig. 1

Flow diagram of the selection of trials for second-line treatments in advanced NSCLC with wild-type or unknown status for EGFR. ° Details in Appendix 6; * Additional articles not identified by searching bibliographic databases; $ 5 trials (10 reports) with chemotherapy (i.e., docetaxel or pemetrexed) at the investigators’ discretion. The last search for randomized trials was conducted on June 6, 2017

Back to article page